HHS-NIH11 · uncategorized

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact...

Deadline

2027-01-07

Funding range

Not listed

Days remaining

181 days

Cost-sharing required

No

Who can apply

  • nonprofits_non_higher_education_without_501c3
  • county_governments
  • small_businesses
  • independent_school_districts
  • other
  • public_and_state_institutions_of_higher_education
  • state_governments
  • nonprofits_non_higher_education_with_501c3
  • public_and_indian_housing_authorities
  • city_or_township_governments
  • other_native_american_tribal_organizations
  • private_institutions_of_higher_education
  • for_profit_organizations_other_than_small_businesses
  • special_district_governments
  • federally_recognized_native_american_tribal_governments

Fit assessment

Overall fit63
Eligibility95
Topic33
Urgency35
  • · Eligibility score 95/100 based on applicant-type gates.
  • · Topic fit 33/100 for education, youth, community keywords.
  • · Deadline urgency 35/100 with 180 days remaining.
  • · Application burden appears low.

Want the full application brief?

One-page grant pack with eligibility checklist, deadline timeline, required documents, application outline, burden estimate, risk flags. Delivered by email within 24 hours.

Sourced from Simpler.Grants.gov. We score every grant the same way. Read our methodology.